Bayer

Member of UN Global Compact

Headquarters in Germany

Bayer website

🔎 Run a search for “Bayer”

Get RSS feed of these results

All stories

Article
21 January 2015
+ Español - Hide

Author: Elva Mendoza, Contralínea (México)

“Transnacionales liberan, por "accidente", 800 toneladas de transgénicos", 18 de enero de 2015...

Read more

Article
13 January 2015

India spurns Gilead over hepatitis C patent

Author: AMy Kazmin & Andrew Ward, Financial Times

India’s patent controller has rejected a patent application from Gilead Sciences for a key compound for its blockbuster hepatitis C drug Sovaldi, a refusal that activists said would allow Indian companies immediately to start producing cheap generic...

Read more

Article
17 December 2014

Bayer loses bid to overturn India's first compulsory licence

Author: Lynne Taylor, Pharmatimes

German drug major Bayer has lost its long-running battle to get India’s first-ever compulsory licence – for its liver and kidney cancer drug Nexavar (sorafenib tosylate) – overturned...The multinational has been seeking to get the compulsory license...

Read more

Article
18 November 2014

Media Kit 2014 Index

Author: Access to Medicines Index

Includes:...

Read more

Article
17 November 2014
+ Español - Hide

Author: Access to Medicines Index

[DOC] “El sector farmacéutico hace más para mejorar el acceso a la medicina en los países en desarrollo, pero su actuación en algunos aspectos es mejorable” - 17 de noviembre de 2014...

Read more

Article
6 October 2014

India: Health activists concerned about affordability of medicines due to US govt. & business pressure

Author: Brook V Baker, Equlibri

Prime Minister Modi is promising to open India to more direct foreign investment and to further liberalize the Indian economy to make it easier for multinational corporations to operate there. To the dismay of health activists worldwide, the US...

Read more

Article
1 July 2014
+ Español - Hide
Article
22 May 2014
+ Français - Hide

Author: Bilan (Suisse)

...Barry Callebaut révèle sa stratégie pour contrer la pénurie: privilégier l'agriculture durable et renoncer aux fèves génétiquement modifiées...Pour [l'entreprise]...qui fournit aussi bien Nestlé que Mondelez ou Mars, la question est cruciale...« .....

Read more

Article
19 February 2014

Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines - company responses/non-responses

Author: Business & Human Rights Resource Centre

In January 2014, the Innovative Pharmaceutical Association of South Africa (IPASA) was accused of planning and funding an advocacy campaign on behalf of its member companies. The campaign allegedly sought to oppose South Africa’s efforts to introduce...

Read more

Company response
18 February 2014

Response by Bayer: Allegations of pharmaceutical group's planned opposition to So. Africa reforms to increase access to medicines

Read full response